| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
The Federation of State Medical Boards (FSMB) is a national non-profit organization representing the 70 medical and osteopathic boards of the United States and its territories.
National Fatherhood Initiative is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The 1725 employees of Columbus Regional Hospital have one clear purpose-to provide the absolute best in patient care. Our doctors, nurses, paramedics, therapists, technicians, and other professionals are trained to do just that.
With our focus on improving patient outcomes with evidence-based healing solutions, we develop, market and distribute biotechnology products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our products are primarily sold in the North American surgical tissue repair and advanced wound care markets.